Trials / Completed
CompletedNCT00286793
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Ascenta Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-101 | Oral |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2006-02-06
- Last updated
- 2011-06-29
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00286793. Inclusion in this directory is not an endorsement.